Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel J Bundred

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Women'S Health (London, England)|October 7, 2009
Letrozole: a well-tolerated and effective treatment for breast cancerNigel J Bundred
BMJ Clinical Evidence|May 21, 2009
Breast painNigel J Bundred
Current Opinion in Obstetrics & Gynecology|January 7, 2009
Aromatase inhibitors and bone healthNigel J Bundred
Expert Review of Anticancer Therapy|December 22, 2007
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?Julie Iddon, Nigel J Bundred
Breast Cancer Research : BCR|January 12, 2005
Do early premalignant changes in normal breast epithelial cells predict cancer development?Robert B Clarke, Nigel J Bundred
Journal of the American College of Surgeons|January 29, 2008
Idiopathic granulomatous mastitis: a 25-year experienceBilal Al-Khaffaf, Fiona Knox, Nigel J Bundred
Microscopy Research and Technique|September 21, 2002
Molecular markers and therapeutic targets in ductal carcinoma in situGary P Boland, W Fiona Knox, Nigel J Bundred
The Journal of Biological Chemistry|November 1, 2003
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinaseTawhid Ahmad, Gillian Farnie, Nigel J Bundred, et al.
Plos One|March 5, 2013
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 statusGillian Farnie, Pamela M Willan, Robert B Clarke, et al.
Nature Reviews. Clinical Oncology|November 5, 2014
Is axillary lymph node clearance required in node-positive breast cancer?Nigel J Bundred, Nicola L P Barnes, Emiel Rutgers, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Women'S Health (London, England)|October 7, 2009
Letrozole: a well-tolerated and effective treatment for breast cancerNigel J Bundred
BMJ Clinical Evidence|May 21, 2009
Breast painNigel J Bundred
Current Opinion in Obstetrics & Gynecology|January 7, 2009
Aromatase inhibitors and bone healthNigel J Bundred
Expert Review of Anticancer Therapy|December 22, 2007
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?Julie Iddon, Nigel J Bundred
Breast Cancer Research : BCR|January 12, 2005
Do early premalignant changes in normal breast epithelial cells predict cancer development?Robert B Clarke, Nigel J Bundred
Journal of the American College of Surgeons|January 29, 2008
Idiopathic granulomatous mastitis: a 25-year experienceBilal Al-Khaffaf, Fiona Knox, Nigel J Bundred
Microscopy Research and Technique|September 21, 2002
Molecular markers and therapeutic targets in ductal carcinoma in situGary P Boland, W Fiona Knox, Nigel J Bundred
The Journal of Biological Chemistry|November 1, 2003
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinaseTawhid Ahmad, Gillian Farnie, Nigel J Bundred, et al.
Plos One|March 5, 2013
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 statusGillian Farnie, Pamela M Willan, Robert B Clarke, et al.
Nature Reviews. Clinical Oncology|November 5, 2014
Is axillary lymph node clearance required in node-positive breast cancer?Nigel J Bundred, Nicola L P Barnes, Emiel Rutgers, et al.
Pageof 5